Market closed
Access this stock data via API
Subscribe
Tekmira Pharmaceuticals Corporation
0
0
0%

Financials

Income statement

Fiscal date 2025 2024 2023 2022
Total reported revenue 11.2B 8.7B 8.7B 9.6B
Cost of revenue 7.4B 5.9B 5.6B 6.2B
Gross profit 3.8B 2.9B 3.1B 3.4B
Operating expense
Research & development
Selling general and admin
Other operating expenses
Operating income 91.4M -123.0M 180.6M 516.6M
Non operating interest income
Income 14.9M 1.3M
Expense 23.8M 10.3M 9.3M 12.1M
Other income expense
Pretax income -78.1M 77.6M 296.7M 623.4M
Tax provision 68.5M 4.6M 33.8M 269.9M
Net income -146.6M 73.1M 262.9M 353.5M
Basic EPS 6.3 22.5 29.5
Diluted EPS 6.2 21.8 28.3
Basic average shares 11.8M 11.7M 12.0M
Diluted average shares 11.8M 11.7M 12.0M
EBITDA 865.4M 295.2M 670.7M 926.3M
Net income from continuing op. -78.1M 77.6M 296.7M 623.4M
Minority interests 6.1M 852K 0 0
Preferred stock dividends 0 0 0 0
Access the full /income_statement historical dataset via the API — starting from the Pro plan.
Market closed

Exchange is currently closed
Main market opens in 16 hours 19 minutes

16:40
00:00
09:00
15:30
23:59

Trading Hours (Monday - Friday):

Main market
09:00 - 15:30
All times are displayed in the Asia/Tokyo timezone (JST, UTC+09:00).